Trends in Cardiovascular Medicine
Volume 16, Issue 3 , Pages 69-75 , April 2006

Estrogen Replacement and Cardiomyocyte Protection

  • Richard D. Patten
    • ,
  • Richard H. Karas

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Richard H. Karas, MD, PhD, Molecular Cardiology Research Institute, NEMC Box#80, 750 Washington Street, Boston, MA 02111, USA. Tel.: (+1) 617-636-8776; fax: (+1) 617-636-1444.

References 

  1. Abbate A, Biondi-Zoccai GGL, Bussani R, et al. Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol. 2003;41:753–760
  2. Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17beta-estradiol- and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol. 1999;58:425–430
  3. Camper-Kirby D, Welch S, Walker A, et al. Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circ Res. 2001;88:1020–1027
  4. Fujio Y, Nguyen T, Wencker D, et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia–reperfusion injury in mouse heart. Circulation. 2000;101:660–667
  5. Ghali JK, Pina IL, Gottlieb SS, et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation. 2002;105:1585–1591
  6. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288:49–57
  7. Guerra S, Leri A, Wang X, et al. Myocyte death in the failing human heart is gender dependent. Circ Res. 1999;85:856–866
  8. Hale SL, Birnbaum Y, Kloner RA. Estradiol, administered acutely, protects ischemic myocardium in both female and male rabbits. J Cardiovasc Pharmacol Ther. 1997;2:47–52
  9. Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res. 2000;87:677–682
  10. Heart Disease and Stroke Statistics . Statistical Supplement. Dallas, TX: American Heart Association; 2005;
  11. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A–13A
  12. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  13. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res. 2000;86:1107–1113
  14. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402
  15. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol. 2003;42:1238–1245
  16. Mani K, Kitsis RN. Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol. 2003;41:761–764
  17. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  18. Matsui T, Tao J, Del Monte F, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation. 2001;104:330–335
  19. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A. 1999;96:8144–8149
  20. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol. 1997;145:269–277
  21. Node K, Kitakaze M, Kosaka H, et al. Amelioration of ischemia- and reperfusion-induced myocardial injury by 17beta-estradiol: role of nitric oxide and calcium-activated potassium channels. Circulation. 1997;96:1953–1963
  22. Nuedling S, Karas RH, Mendelsohn ME, et al. Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Lett. 2001;502:103–108
  23. Olivetti G, Giordano G, Corradi D, et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol. 1995;26:1068–1079
  24. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131–1141
  25. Patten RD, Aronovitz MJ, Deras-Mejia L, et al. Ventricular remodeling in a mouse model of myocardial infarction. Am J Physiol Heart Circ J. 1998;274:H1812–H1820
  26. Patten RD, Pourati I, Aronovitz MJ, et al. 17{beta}-Estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res. 2004;95:692–699
  27. Pelzer T, Schumann M, Neumann M, et al. 17beta-Estradiol prevents programmed cell death in cardiac myocytes. Biochem Biophys Res Commun. 2000;268:192–200
  28. Pelzer T, Neumann M, De Jager T, et al. Estrogen effects in the myocardium: inhibition of NF-[kappa]B DNA binding by estrogen receptor-[alpha] and -[beta]. Biochem Biophys Res Commun. 2001;286:1153–1157
  29. Reis SE, Holubkov R, Young JB, et al. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. J Am Coll Cardiol. 2000;36:529–533
  30. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA. 2002;288:321–333
  31. Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation. 1997;95:320–323
  32. Saraste A, Pulkki K, Kallajoki M, et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest. 1999;29:380–386
  33. Shlipak MG, Angeja BG, Go AS, et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 2001;104:2300–2304
  34. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation. 2001;103:375–380
  35. Simoncini T, Hafezi-Moghadam A, Brazil DP, et al. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature. 2000;407:538–541
  36. Sugden PH, Clerk A. Akt like a woman: gender differences in susceptibility to cardiovascular disease. Circ Res. 2001;88:975–977
  37. Van Eickels M, Patten RD, Aronovitz MJ, et al. 17-Beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol. 2003;41:2084–2092
  38. Van Empel VPM, De Windt LJ. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovascular Research. 2004;63:487–499
  39. Yu X, Rajala RVS, McGinnis JF, et al. Involvement of insulin/phosphoinositide 3-kinase/Akt signal pathway in 17{beta}-estradiol-mediated neuroprotection. J Biol Chem. 2004;279:13086–13094
  40. Zhai P, Eurell TE, Cooke PS, et al. Myocardial ischemia–reperfusion injury in estrogen receptor-alpha knockout and wild-type mice. Am J Physiol Heart Circ Physiol. 2000;278:H1640–H1647

PII: S1050-1738(06)00003-X

doi: 10.1016/j.tcm.2006.01.002

Trends in Cardiovascular Medicine
Volume 16, Issue 3 , Pages 69-75 , April 2006

Article Tools

* Image Usage & Resolution